Menu
In October 2024, it will be possible to exercise the warrants of series TO7 issued in connection with the rights issue conducted in December 2023. The subscription period will run from and including October 7, 2024, up to and including October 18, 2024. Each warrant of series TO7 entitles the holder the right to subscribe for one (1) new share in Prolight Diagnostics AB. Please note that warrants of series TO7 that are not exercised at latest October 18, 2024, or sold at the least on October 15, 2024, will expire without value.
Exercise period:
October 7, 2024 – October 18, 2024.
Exercise price:
Issue size:
108,756,747 warrants of series TO7 entitling to subscription of 108,756,747 shares. If all the warrants are exercised the Company will receive approximately SEK 13.1 million before issuing costs.
Last day for trading with warrants of series TO7: October 15, 2024.
Dilution:
If all warrants of series TO7 are exercised the total number of shares in the Company will increase by 108,756,747, from 597,287,105 shares to 706,043,852 shares, and the share capital will increase with SEK 10,875,674.70, from SEK 59,728,710.50 to SEK 70,604,385.20. This corresponds to a maximum dilution of approximately 15.4 percent of the total number of shares and 15.4 percent of the total number of votes in the Company.
Note that the warrants that are not exercised at latest on October 18, 2024, or sold at the latest on October 15, 2024, will expire without value. For the warrants not to lose their value, the holder must actively exercise the warrants for subscription of new shares or sell the warrants. Please observe that certain nominees might close their application earlier than October 18, 2024.
Full terms and conditions for the warrants of series TO7: Klick here!
Nominee-registered warrants (custody)
Subscription and payment by exercise of the warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Directly registered warrants (VP account)
No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at the Swedish Companies Registration Office.
The prospectus and offerings may NOT be downloaded or read by persons residing in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where participation would require additional prospectuses, registration, or measures other than those under Swedish law or otherwise contrary to the rules of such jurisdiction. Distribution of the Prospectus and offerings and participation in the Offer are subject to restrictions in law and other rules in some jurisdictions. The Company has not taken and will not take any steps to allow an offer to the public in any jurisdictions other than Sweden. The Offer is not addressed to persons domiciled in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where participation would require additional prospectuses, registration, or other measures than those arising under Swedish law or otherwise contrary to the rules of such jurisdiction. Consequently, the prospectus, the notification form and other documents relating to the Offer may not be distributed in or to said countries or any other jurisdiction where distribution or the Offer requires such action or otherwise violates applicable rules. Subscription of units and acquisition of securities in violation of the above limitations may be invalid. Persons receiving copies of the Prospectus must inform themselves of and comply with such restrictions. Measures in breach of the restrictions may constitute a breach of applicable securities laws. You can find the documents with restricted access below.